|
US4903164A
(en)
|
1988-12-08 |
1990-02-20 |
Texas Instruments Incorporated |
O-ring/back-up ring seal for high pressure transducers
|
|
CA2264819C
(en)
*
|
1996-09-04 |
2010-03-23 |
Intertrust Technologies Corp. |
Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
|
|
EP2081905B1
(en)
|
2006-07-28 |
2012-09-12 |
Boehringer Ingelheim International GmbH |
Sulfonyl compounds which modulate the cb2 receptor
|
|
WO2008023159A1
(en)
|
2006-08-24 |
2008-02-28 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
|
|
EP2074084B1
(en)
|
2006-09-25 |
2013-08-28 |
Boehringer Ingelheim International GmbH |
Compounds which modulate the cb2 receptor
|
|
EP2118069B1
(en)
*
|
2007-01-09 |
2014-01-01 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
|
AU2008213808B2
(en)
*
|
2007-02-06 |
2011-11-10 |
Novartis Ag |
PI 3-kinase inhibitors and methods of their use
|
|
EP2176238B1
(en)
*
|
2007-07-09 |
2012-04-18 |
AstraZeneca AB |
Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
|
|
BRPI0814818A2
(pt)
*
|
2007-07-09 |
2019-09-10 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
|
|
CA2704684A1
(en)
|
2007-11-07 |
2009-05-14 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
US9029411B2
(en)
|
2008-01-25 |
2015-05-12 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and uses thereof
|
|
US8946439B2
(en)
|
2008-02-29 |
2015-02-03 |
Evotec Ag |
Amide compounds, compositions and uses thereof
|
|
EP2283001A2
(en)
*
|
2008-05-13 |
2011-02-16 |
Boehringer Ingelheim International GmbH |
Sulfone compounds which modulate the cb2 receptor
|
|
EP2294072B1
(en)
*
|
2008-05-23 |
2017-03-29 |
Wyeth LLC |
Triazine compounds as p13 kinase and mtor inhibitors
|
|
MX2010014125A
(es)
*
|
2008-06-19 |
2011-02-24 |
Millennium Pharm Inc |
Derivados de tiofeno o tiazol y su uso como inhibidores de p13k.
|
|
US8178568B2
(en)
|
2008-07-10 |
2012-05-15 |
Boehringer Ingelheim International Gmbh |
Sulfone compounds which modulate the CB2 receptor
|
|
WO2010014939A1
(en)
*
|
2008-07-31 |
2010-02-04 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
|
EP2342191B1
(en)
|
2008-09-10 |
2013-03-20 |
Mitsubishi Tanabe Pharma Corporation |
Aromatic nitrogen-containing 6-membered ring compounds and their use
|
|
CA2737038A1
(en)
|
2008-09-18 |
2010-03-25 |
Evotec Ag |
Amide compounds, compositions and uses thereof
|
|
WO2010036631A2
(en)
|
2008-09-25 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
CA2750935A1
(en)
|
2009-01-30 |
2010-08-12 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and their use as pi3k inhibitors
|
|
US8796314B2
(en)
|
2009-01-30 |
2014-08-05 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
EP2406258B1
(en)
|
2009-03-13 |
2014-12-03 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
CA2755554C
(en)
*
|
2009-04-17 |
2013-09-24 |
Wyeth Llc |
Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
WO2010120996A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
WO2010120991A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
|
|
WO2010125799A1
(ja)
*
|
2009-04-27 |
2010-11-04 |
塩野義製薬株式会社 |
Pi3k阻害活性を有するウレア誘導体
|
|
US8299103B2
(en)
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
|
US8383615B2
(en)
|
2009-06-16 |
2013-02-26 |
Boehringer Ingelheim International Gmbh |
Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
|
|
PL2442809T3
(pl)
|
2009-06-17 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitory replikacji wirusów grypy
|
|
EP2445346A4
(en)
*
|
2009-06-24 |
2012-12-05 |
Genentech Inc |
OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
|
|
EP2480544A1
(en)
|
2009-09-22 |
2012-08-01 |
Boehringer Ingelheim International GmbH |
Compounds which selectively modulate the cb2 receptor
|
|
EA201290255A1
(ru)
|
2009-10-30 |
2013-04-30 |
Ариад Фармасьютикалз, Инк. |
Способы и композиции для лечения рака
|
|
JP5579864B2
(ja)
|
2009-11-12 |
2014-08-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｎ−９−置換プリン化合物、組成物及び使用の方法
|
|
EP2499143B1
(en)
|
2009-11-12 |
2016-03-16 |
F.Hoffmann-La Roche Ag |
N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
EP2523936A1
(en)
|
2010-01-15 |
2012-11-21 |
Boehringer Ingelheim International GmbH |
Compounds which modulate the cb2 receptor
|
|
WO2011107585A1
(en)
|
2010-03-04 |
2011-09-09 |
Cellzome Limited |
Morpholino substituted urea derivatives as mtor inhibitors
|
|
JP5746228B2
(ja)
|
2010-03-05 |
2015-07-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を選択的に調節するテトラゾール化合物
|
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
|
WO2012012307A1
(en)
|
2010-07-22 |
2012-01-26 |
Boehringer Ingelheim International Gmbh |
Sulfonyl compounds which modulate the cb2 rece
|
|
EP2603214A4
(en)
|
2010-08-11 |
2013-12-18 |
Millennium Pharm Inc |
HETEROARYLE AND USES THEREOF
|
|
EP2603216A4
(en)
|
2010-08-11 |
2013-12-18 |
Millennium Pharm Inc |
HETEROARYLE AND USES THEREOF
|
|
WO2012021611A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
SG188439A1
(en)
|
2010-10-01 |
2013-05-31 |
Novartis Ag |
Manufacturing process for pyrimidine derivatives
|
|
EP2627181A4
(en)
|
2010-10-13 |
2014-03-19 |
Millennium Pharm Inc |
HETEROARYLE AND USES THEREOF
|
|
WO2012058671A1
(en)
|
2010-10-31 |
2012-05-03 |
Endo Pharmaceuticals Inc. |
Substituted quinazoline and pyrido-pyrimidine derivatives
|
|
JP2014510122A
(ja)
|
2011-04-04 |
2014-04-24 |
セルゾーム リミテッド |
ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
|
|
CN102887867B
(zh)
*
|
2011-07-21 |
2015-04-15 |
中国科学院上海药物研究所 |
一类三嗪类化合物、该化合物的制备方法及其用途
|
|
KR20140049026A
(ko)
*
|
2011-07-26 |
2014-04-24 |
그뤼넨탈 게엠베하 |
바닐로이드 수용체 리간드로서의 치환된 헤테로방향족 피라졸―함유 카복스아미드 및 우레아 유도체
|
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
|
ES2643235T3
(es)
*
|
2011-09-02 |
2017-11-21 |
Purdue Pharma Lp |
Pirimidinas como bloqueantes del canal de sodio
|
|
WO2013041652A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
|
WO2013050508A1
(en)
|
2011-10-07 |
2013-04-11 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
|
|
WO2013174794A1
(en)
|
2012-05-23 |
2013-11-28 |
F. Hoffmann-La Roche Ag |
Compositions and methods of obtaining and using endoderm and hepatocyte cells
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
US9296727B2
(en)
|
2013-10-07 |
2016-03-29 |
Vertex Pharmaceuticals Incorporated |
Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
|
|
EP3421468B1
(en)
|
2013-11-13 |
2020-11-04 |
Vertex Pharmaceuticals Incorporated |
Methods of preparing inhibitors of influenza viruses replication
|
|
LT3068776T
(lt)
|
2013-11-13 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Gripo virusų replikacijos inhibitoriai
|
|
EP3145916B1
(en)
*
|
2014-05-21 |
2020-02-12 |
Allergan, Inc. |
Imidazole derivatives as formyl peptide receptor modulators
|
|
US10689383B2
(en)
|
2014-08-04 |
2020-06-23 |
Nuevolution A/S |
Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
|
|
JP6704416B2
(ja)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
インフルエンザウイルスの複製の阻害剤を調製する方法
|
|
WO2016183120A1
(en)
|
2015-05-13 |
2016-11-17 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
|
EP3630116B1
(en)
|
2017-05-26 |
2024-05-01 |
The Board Of Regents Of The University Of Texas System |
Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
|
|
SI3651768T1
(sl)
|
2017-07-13 |
2024-05-31 |
Chempartner Corporation |
Heterociklični inhibitorji atr kinaze
|
|
JP7290627B2
(ja)
|
2017-08-17 |
2023-06-13 |
ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム |
Ａｔｒキナーゼの複素環式阻害剤
|
|
JP7341156B2
(ja)
|
2018-03-16 |
2023-09-08 |
ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム |
Ａｔｒキナーゼの複素環式阻害剤
|
|
PE20230240A1
(es)
|
2019-12-20 |
2023-02-07 |
Nuevolution As |
Compuestos activos frente a receptores nucleares
|
|
MX2022007265A
(es)
|
2019-12-20 |
2022-09-09 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
AU2021245397A1
(en)
|
2020-03-31 |
2022-10-20 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
JP7713954B2
(ja)
|
2020-03-31 |
2025-07-28 |
ヌエヴォリューション・アクティーゼルスカブ |
核内受容体に対して活性な化合物
|